| [1] |
Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA):an open-label,single-group,multicentre,phase 2 trial[J]. Lancet Oncol,2017,18(4):545-554.
|
| [2] |
Shu S, Lin CY, He HH, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer[J]. Nature,2016,529(7586):413-417.
|
| [3] |
Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer[J]. N Engl J Med,2016,375(1):23-34.
|
| [4] |
Mayer IA, Abramson VG, Lehmann BD, et al. New strategies for triple-negative breast cancer--deciphering the heterogeneity[J]. Clin Cancer Res,2014,20(4):782-790.
|
| [5] |
Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer[J]. Oncology,2015,29(5):375-385.
|
| [6] |
Yeong J, Thike AA, Lim JC, et al. Higher densities of Foxp3 +regulatory T cells are associated with better prognosis in triple-negative breast cancer[J].Breast Cancer Res Treat,2017,163(1):21-35.
|
| [7] |
Cecil DL, Slota M, O'Meara MM, et al. Immunization against HIF-1α inhibits the growth of basal mammary tumors and targets mammary stem cells in vivo[J]. Clin Cancer Res,2017,23(13):3396-3404.
|
| [8] |
Harao M, Forget MA, Roszik J, et al. 4-1BB-enhanced expansion of CD8+ TIL from triple-negative breast cancer unveils mutation-specific CD8+ T cells[J]. Cancer Immunol Res,2017,5(6):439-445.
|
| [9] |
Chandra D, Jahangir A, Cornelis F, et al. Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer[J].Oncoimmunology,2015,5(1): e1049802.
|
| [10] |
Kunert A, van Brakel M. MAGE-C2-specific TCRs combined with epigenetic grug-enhanced antigenicity yield robust and tumor-selective T cell responses[J]. J Immunol,2016,197(6):2541-2552.
|
| [11] |
Song DG, Ye Q, Poussin M, et al. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level[J]. J Hematol Oncol,2016,9(1):56.
|
| [12] |
Tchou J, Wang LC, Selven B, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer[J]. Breast Cancer Res Treat,2012,133(2):799-804.
|
| [13] |
Balakrishnan A, Goodpaster T, Randolph-Habecker J, et al. Analysis of ROR1 protein expression in human cancer and normal tissues[J].Clin Cancer Res,2017,23(12):3061-3071.
|
| [14] |
Zhang P,Yi S,Li X,et al. Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells[J]. PLoS One,2014,9(7): e102197.
|
| [15] |
Paret C, Simon P, Vormbrock K, et al. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer[J]. Oncotarget,2015,6(28):25 356-25 367.
|
| [16] |
Piechocki MP, Wu GS, Jones RF, et al. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA[J]. Int J Cancer,2012,131(11):2562-2572.
|
| [17] |
Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies [J]. Cancer Res, 2012, 72 (13):3163-3174.
|
| [18] |
Gujam FJ,Edwards J,Mohammed ZM,et al. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer [J]. Br J Cancer,2014,111(1):157-165.
|
| [19] |
Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer[J]. J Immunother Cancer,2016,4:59.
|
| [20] |
Mao Y, Qu Q, Chen X, et al. The prognostic value of tumorinfiltrating lymphocytes in breast cancer: a systematic review and metaanalysis[J]. PLoS One,2016,11(4): e0152500.
|
| [21] |
Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study[J].Breast Cancer Res,2015,17:124.
|
| [22] |
Asano Y, Kashiwagi S, Goto W, et al. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer[J]. Br J Surg,2016,103(7):845-854.
|
| [23] |
Mella M, Kauppila JH, Karihtala P, et al. Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naive triple negative breast cancer and renal cell carcinoma [J].Oncoimmunology,2015,4(6): e1002726.
|
| [24] |
Chen Z, Chen X, Zhou E, et al. Intratumoral CD8(+) cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer[J]. PLoS One,2014,9(4): e95475.
|
| [25] |
Liu S, Lachapelle J,Leung S,et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer[J]. Breast Cancer Res,2012,14(2): R48.
|
| [26] |
Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+T-cell infiltration and breast cancer survival in 12,439 patients[J].Ann Oncol,2014,25(8):1536-1543.
|
| [27] |
Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer[J]. Cancer Immunol Res,2014,2(4):361-370.
|
| [28] |
Matsumoto H, Koo SL, Dent R, et al. Role of inflammatory infiltrates in triple negative breast cancer[J]. J Clin Pathol, 2015, 68(7):506-510.
|
| [29] |
张欢,吴斌. 乳腺癌免疫治疗的研究进展[J/CD]. 中华乳腺病杂志(电子版),2015,9(4):264-269.
|